September 8, 2017
A Japanese patent (6205363) was issued for JN Biosciences' MultYmab™ antibody engineering technology. This patent covers multimeric antibodies and Fc fusion proteins generated by the MultYmab™ technology that bind to and crosslink surface molecules and induce intracellular signaling.
May 12 - 16, 2017
Therapeutic efficacy of an anti-CD122 IgG antibody in the mouse model of type I diabetes was presented by Dr. Wenxian Fu's group of University of California at San Diego at the American Association of Immunologists Meeting in Washington D.C. (click here for the abstract).
The efficacy of an anti-CD122 IgG antibody for treatment of vitiligo in the mouse model was presented by Dr. John Harris' group of University of Massachusetts at the American Association of Immunologists Meeting in Washington D.C. (click here for the abstract).
March 19 - 23, 2017
The data showing the biological activity of AB154, a humaized anti-TIGIT IgG antibody, which is expected to induce a strong anti-cancer immune response in humans, was presented at the Keystone Symposia - Cancer Immunology and Immunotherapy in Whistler, British Columbia, Canada (click here for the abstract).
January 10, 2017
A new U.S. patent (9540442) was issued for JN Biosciences' MultYmab™ antibody engineering technology, which has been used for generation of an alternative form of hexameric IgG antibodies that function as potent agonists against costimulatory molecules for cancer immunotherapy.
